Merck &

MRK Healthcare & Pharma 4/10 Medium Risk

4/10

↑ 1 → 4 over 22 weeks

Sector avg: 3.1/10

Merck & carries $49.1B in long-term debt, with $13.1B in scheduled principal maturities. Notably, the entire $13.1B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores MRK at 4/10, indicating moderate refinancing pressure.

Maturity Schedule

As of 2025-12-31 (latest SEC filing with maturity data). Debt actions taken after this date will only appear once SEC processes the relevant XBRL filing.

Period	Amount Due	% of Total
Year 1 (0-12 months)	$2.6B	19.8%
Year 2 (12-24 months)	$2.7B	20.6%
Year 3 (24-36 months)	$2.1B	16.0%
Year 4 (36-48 months)	$3.0B	22.9%
Year 5 (48-60 months)	$2.7B	20.6%
Beyond 5 Years	N/A	N/A
Total Scheduled Maturities	$13.1B	100.0%

Why don't these totals match? Total scheduled maturities ($13.1B) falls short of balance-sheet long-term debt ($49.1B) by about 73%. The two figures come from different disclosures: the maturity schedule aggregates gross principal repayments from the debt footnote — typically including the current portion of long-term debt and sometimes finance leases — while balance-sheet long-term debt is a carrying value that excludes the current portion and is net of unamortized discounts, premiums, and issuance costs. They can also come from filings with different period-end dates (2025-12-31 vs 2026-03-31). Both numbers are shown exactly as reported to the SEC.

Key Metrics

Total Long-Term Debt

$49.1B

Near-Term (12mo)

$2.6B

Interest Coverage

N/A

Debt/Equity

1.07

Cash Coverage

2.05x

Operating Income

N/A

How This Score Was Computed

Weighted average of 3 scored components (raw 4.47, rounded to 4). Weights of skipped components are redistributed proportionally among those scored.

Component	Value	Sub-Score	Weight Used
Near-Term Maturity Concentration Show calculation Year-1 maturities / Total scheduled maturities Year-1 maturities: $2.6B Total scheduled maturities: $13.1B	19.8%	5/10	40%
Interest Coverage Ratio Operating income was not reported in the latest 10-K.	N/A	—	not scored
Debt-to-Equity Ratio Show calculation Long-term debt / Stockholders' equity Long-term debt: $49.1B Stockholders' equity: $45.9B	1.07	5/10	33%
Cash Coverage of Near-Term Debt Show calculation Cash & equivalents / Debt due within 12 months Cash & equivalents: $5.3B Near-term debt: $2.6B	2.05x	3/10	27%
Cash Runway Only scored when a company is burning cash. Operating cash flow is positive (or unreported), so runway isn't a constraint.	N/A	—	not scored

"Weight Used" shows each component's share after the weights of unscored components are redistributed. Full thresholds and formulas are on the methodology page.

Recent SEC Filings

Material disclosures from Merck &'s most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date	Form	Details
2026-05-28	8-K	Shareholder Vote
2026-05-22	8-K	Other Events
2026-05-20	424B5	Prospectus supplement — possible debt or equity issuance
2026-05-18	424B5	Prospectus supplement — possible debt or equity issuance
2026-05-04	10-Q	Quarterly report
2026-04-30	8-K	Earnings Results
2026-04-08	DEFA14A	Additional proxy materials
2026-04-08	DEF 14A	Proxy statement

Related Companies

Johnson & Johnson

JNJ

1/10

Debt: $41.4B 12mo: $2.0B

Pfizer

PFE

5/10

Debt: N/A 12mo: $3.9B

AbbVie

ABBV

4/10

Debt: $64.5B 12mo: $6.0B

Eli Lilly

LLY

4/10

Debt: $29.5B 12mo: N/A

Bristol Myers Squibb

BMY

5/10

Debt: $44.1B 12mo: $2.0B

Amgen

AMGN

5/10

Debt: $57.3B 12mo: $4.6B

Gilead Sciences

GILD

2/10

Debt: $22.2B 12mo: $1.3B

Regeneron Pharmaceuticals

REGN

1/10

Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-31. Filing date: 2026-05-04. Data last fetched: 2026-07-26. Maturity schedules reflect the company's most recently reported debt repayment obligations. This company does not tag the standard LongTermDebt concept; its debt figure comes from DebtLongtermAndShorttermCombinedAmount. Data quality: Partial.
View SEC EDGAR filings for Merck & →